Clinical Trials Logo

Clinical Trial Summary

A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03521908
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase
Start date June 13, 2016
Completion date November 23, 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03265054 - Evaluation of the Predictive Value of the Microvesicle Coagulo-lytic Balance in the Recurrence of Venous Thrombosis N/A
Completed NCT04141228 - A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US
Completed NCT01119274 - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Phase 4
Completed NCT03965741 - Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Completed NCT02798471 - Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Phase 3
Completed NCT01583218 - Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Phase 3
Recruiting NCT03802929 - Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism
Completed NCT02073682 - Cancer Venous Thromboembolism (VTE) Phase 3
Completed NCT03977870 - Identification of New Genetic Markers for the Risk of Recurrence of Venous Thromboembolism by Whole Genome Analysis
Recruiting NCT06057844 - Molecular Imaging of Active Venous Thrombus With Positron Emission Tomography (PET) N/A
Active, not recruiting NCT04243122 - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Phase 2
Recruiting NCT02156401 - VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE